Skip to main content
Top
Published in: Lung 5/2016

01-10-2016

The Roles of the Charlson Comorbidity Index and Time to First Antibiotic Dose as Predictors of Outcome in Pneumococcal Community-Acquired Pneumonia

Authors: Daniel Franzen, Marisa Lim, Daniel J. Bratton, Stefan P. Kuster, Malcolm Kohler

Published in: Lung | Issue 5/2016

Login to get access

Abstract

Purpose

In this retrospective study, we aimed to investigate the role of comorbidities using the Charlson comorbidity index (CCI) and time to first antibiotic dose (TFAD) in patients with pneumococcal community-acquired pneumonia (PCAP).

Methods

All consecutive ER admissions with PCAP who were hospitalized in the University Hospital, Zurich between 2006 and 2012 were included. The primary outcome was to determine possible determinants of all-cause in-hospital mortality (ACIHM). The second endpoint was to detect risk factors for adverse events (AEs) and determinants of length of stay (LOS).

Results

108 subjects (mean age 57.6 years) were included. The median (IQR) CCI was 4 (1, 8). The median (IQR) TFAD was 210 (150, 280) min. ACIHM was 6.5 % (7/108), and median (IQR) LOS was 9 (6, 14) days. PCAP-related AEs were observed in 57 cases (52.8 %). In the multivariable analysis, neither CCI nor TFAD was associated with the outcome measures. Pneumonia severity index (PSI) was the only statistically significant predictor of ACIHM (HR 1.31/10 point increase, 95 % CI 1.12–1.53, p = 0.001) and AE rate (OR 1.31, 95 % CI 1.15–1.50, p < 0.001).

Conclusions

In this study including comparatively young patients with rather mild disease severity, we found no strong evidence supporting that CCI or TFAD influenced short-term outcome measures of PCAP. Yet, pneumonia severity appears to be the most important factor for the outcome.
Literature
1.
go back to reference Waterer GW, Kessler LA, Wunderink RG (2006) Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest 130:11–15CrossRefPubMed Waterer GW, Kessler LA, Wunderink RG (2006) Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest 130:11–15CrossRefPubMed
2.
go back to reference Wesemann T, Nullmann H, Pflug MA et al (2015) Pneumonia severity, comorbidity and 1-year mortality in predominantly older adults with community-acquired pneumonia: a cohort study. BMC Infect Dis 15:2CrossRefPubMedPubMedCentral Wesemann T, Nullmann H, Pflug MA et al (2015) Pneumonia severity, comorbidity and 1-year mortality in predominantly older adults with community-acquired pneumonia: a cohort study. BMC Infect Dis 15:2CrossRefPubMedPubMedCentral
3.
go back to reference Garnacho-Montero J, Garcia-Cabrera E, Diaz-Martin A et al (2010) Determinants of outcome in patients with bacteraemic pneumococcal pneumonia: importance of early adequate treatment. Scand J Infect Dis 42:185–192CrossRefPubMed Garnacho-Montero J, Garcia-Cabrera E, Diaz-Martin A et al (2010) Determinants of outcome in patients with bacteraemic pneumococcal pneumonia: importance of early adequate treatment. Scand J Infect Dis 42:185–192CrossRefPubMed
4.
go back to reference Houck PM, Bratzler DW (2005) Administration of first hospital antibiotics for community-acquired pneumonia: does timeliness affect outcomes? Curr Opin Infect Dis 18:151–156CrossRefPubMed Houck PM, Bratzler DW (2005) Administration of first hospital antibiotics for community-acquired pneumonia: does timeliness affect outcomes? Curr Opin Infect Dis 18:151–156CrossRefPubMed
5.
go back to reference Bruns AH, Oosterheert JJ, Hustinx WN et al (2009) Time for first antibiotic dose is not predictive for the early clinical failure of moderate-severe community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 28:913–919CrossRefPubMedPubMedCentral Bruns AH, Oosterheert JJ, Hustinx WN et al (2009) Time for first antibiotic dose is not predictive for the early clinical failure of moderate-severe community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 28:913–919CrossRefPubMedPubMedCentral
6.
go back to reference Cheng AC, Buising KL (2009) Delayed administration of antibiotics and mortality in patients with community-acquired pneumonia. Ann Emerg Med 53:618–624CrossRefPubMed Cheng AC, Buising KL (2009) Delayed administration of antibiotics and mortality in patients with community-acquired pneumonia. Ann Emerg Med 53:618–624CrossRefPubMed
7.
go back to reference Yahav D, Leibovici L, Goldberg E et al (2013) Time to first antibiotic dose for patients hospitalised with community-acquired pneumonia. Int J Antimicrob Agents 41:410–413CrossRefPubMed Yahav D, Leibovici L, Goldberg E et al (2013) Time to first antibiotic dose for patients hospitalised with community-acquired pneumonia. Int J Antimicrob Agents 41:410–413CrossRefPubMed
8.
go back to reference Sucov A, Valente J, Reinert SE (2013) Time to first antibiotics for pneumonia is not associated with in-hospital mortality. J Emerg Med 45:1–7CrossRefPubMed Sucov A, Valente J, Reinert SE (2013) Time to first antibiotics for pneumonia is not associated with in-hospital mortality. J Emerg Med 45:1–7CrossRefPubMed
9.
go back to reference Bordon J, Aliberti S, Duvvuri P et al (2013) Early administration of the first antimicrobials should be considered a marker of optimal care of patients with community-acquired pneumonia rather than a predictor of outcomes. Int J Infect Dis 17:e293–e298CrossRefPubMed Bordon J, Aliberti S, Duvvuri P et al (2013) Early administration of the first antimicrobials should be considered a marker of optimal care of patients with community-acquired pneumonia rather than a predictor of outcomes. Int J Infect Dis 17:e293–e298CrossRefPubMed
10.
go back to reference Silber SH, Garrett C, Singh R et al (2003) Early administration of antibiotics does not shorten time to clinical stability in patients with moderate-to-severe community-acquired pneumonia. Chest 124:1798–1804CrossRefPubMed Silber SH, Garrett C, Singh R et al (2003) Early administration of antibiotics does not shorten time to clinical stability in patients with moderate-to-severe community-acquired pneumonia. Chest 124:1798–1804CrossRefPubMed
11.
go back to reference Lujan M, Gallego M, Belmonte Y et al (2010) Influence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia. Eur Respir J 36:1073–1079CrossRefPubMed Lujan M, Gallego M, Belmonte Y et al (2010) Influence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia. Eur Respir J 36:1073–1079CrossRefPubMed
12.
go back to reference Giner AM, Kuster SP, Zbinden R et al (2011) Initial management of and outcome in patients with pneumococcal bacteremia: a retrospective study at a Swiss university hospital, 2003–2009. Infection 39:519–526CrossRefPubMed Giner AM, Kuster SP, Zbinden R et al (2011) Initial management of and outcome in patients with pneumococcal bacteremia: a retrospective study at a Swiss university hospital, 2003–2009. Infection 39:519–526CrossRefPubMed
13.
go back to reference Christensen JS, Jensen TG, Kolmos HJ et al (2012) Bacteremia with Streptococcus pneumoniae: sepsis and other risk factors for 30-day mortality–a hospital-based cohort study. Eur J Clin Microbiol Infect Dis 31:2719–2725CrossRefPubMed Christensen JS, Jensen TG, Kolmos HJ et al (2012) Bacteremia with Streptococcus pneumoniae: sepsis and other risk factors for 30-day mortality–a hospital-based cohort study. Eur J Clin Microbiol Infect Dis 31:2719–2725CrossRefPubMed
14.
go back to reference Bordon J, Peyrani P, Brock GN et al (2008) The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study. Chest 133:618–624CrossRefPubMed Bordon J, Peyrani P, Brock GN et al (2008) The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study. Chest 133:618–624CrossRefPubMed
15.
go back to reference Mandell LA, Wunderink RG, Anzueto A et al (2007) Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27–S72CrossRefPubMed Mandell LA, Wunderink RG, Anzueto A et al (2007) Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27–S72CrossRefPubMed
16.
go back to reference Lim WS, van der Eerden MM, Laing R et al (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58:377–382CrossRefPubMedPubMedCentral Lim WS, van der Eerden MM, Laing R et al (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58:377–382CrossRefPubMedPubMedCentral
17.
go back to reference Fine MJ, Auble TE, Yealy DM et al (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243–250CrossRefPubMed Fine MJ, Auble TE, Yealy DM et al (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243–250CrossRefPubMed
18.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefPubMed
19.
go back to reference Sharabiani MT, Aylin P, Bottle A (2012) Systematic review of comorbidity indices for administrative data. Med Care 50:1109–1118CrossRefPubMed Sharabiani MT, Aylin P, Bottle A (2012) Systematic review of comorbidity indices for administrative data. Med Care 50:1109–1118CrossRefPubMed
20.
go back to reference Nazarian DJ, Eddy OL, Lukens TW, Weingart SD, Decker WW (2009) Clinical policy: critical issues in the management of adult patients presenting to the emergency department with community-acquired pneumonia. Ann Emerg Med 54:704–731CrossRefPubMed Nazarian DJ, Eddy OL, Lukens TW, Weingart SD, Decker WW (2009) Clinical policy: critical issues in the management of adult patients presenting to the emergency department with community-acquired pneumonia. Ann Emerg Med 54:704–731CrossRefPubMed
21.
go back to reference Lim WS, Baudouin SV, George RC et al (2009) BTS guidelines for the management of community acquired pneumonia in adults update 2009. Thorax 64(Suppl 3):iii1–iii55CrossRefPubMed Lim WS, Baudouin SV, George RC et al (2009) BTS guidelines for the management of community acquired pneumonia in adults update 2009. Thorax 64(Suppl 3):iii1–iii55CrossRefPubMed
22.
go back to reference Lee JS, Giesler DL, Gellad WF et al (2016) Antibiotic Therapy for adults hospitalized with community-acquired pneumonia: a systematic review. JAMA 315:593–602CrossRefPubMed Lee JS, Giesler DL, Gellad WF et al (2016) Antibiotic Therapy for adults hospitalized with community-acquired pneumonia: a systematic review. JAMA 315:593–602CrossRefPubMed
Metadata
Title
The Roles of the Charlson Comorbidity Index and Time to First Antibiotic Dose as Predictors of Outcome in Pneumococcal Community-Acquired Pneumonia
Authors
Daniel Franzen
Marisa Lim
Daniel J. Bratton
Stefan P. Kuster
Malcolm Kohler
Publication date
01-10-2016
Publisher
Springer US
Published in
Lung / Issue 5/2016
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-016-9922-z

Other articles of this Issue 5/2016

Lung 5/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.